Tempus IPS
Overview
Understand immune checkpoint inhibitor (ICI) treatment response
IPS is an AI-developed algorithm providing prognostic insights into real-world overall survival (rwOS) outcomes for ICI treatment in metastatic solid tumors.
Refine IO biomarker detection with IPS
Despite advancements in biomarker testing, the need for more sensitive and generalizable biomarkers to predict ICI treatment outcomes still remains. The development of reliable predictors has been hindered by limited access to multi-omic testing and substantial validation cohorts. IPS helps address these challenges as a DNA- and RNA-based molecular signature that demonstrates prognostic utility in an overall pan-cancer cohort of metastatic solid tumor patients receiving ICI-based regimens.
The information on this page is intended for life sciences partners and focuses on research and development applications.
Test design
IPS provides an “Immune Profile Score” ranging from 0 to 100 and classifies patients into two groups*
- IPS-High: Indicates longer rwOS in patients receiving ICI-based regimens.
- IPS-Low: Indicates shorter rwOS in patients receiving ICI-based regimens.
*Some patients will have Indeterminate results. The Indeterminate range of 45-47 accounts for assay variability; therefore the sample cannot be reliably classified as IPS-High or IPS-Low.
Clinical validation of a novel multi-omic algorithm for stratifying outcomes in a real-world cohort of metastatic solid cancer patients treated with immune checkpoint inhibitors
A prospective-retrospective validation in 1,519 patients demonstrated strong stratification of overall survival (OS) (hazard ratio [HR]=0.45 [0.41-0.57]) in the overall cohort, showing significantly longer OS in IPS-High patients.
Features
Comprehensive analysis
IPS combines DNA and RNA biomarkers for a robust prognostic score.Pan-cancer applicability
Applicable to a wide range of solid tumors, supporting broad research applications.Enhanced stratification
IPS aids in identifying patient populations who may respond favorably to ICI therapies.Research-ready
IPS can be added to concurrent Tempus xT and xR test orders without requiring additional tissue samples or wet lab assays.Data-driven
Validated in 1,500+ pan-cancer patients, ensuring the reliability and robustness of the IPS algorithm.Strong partnership potential
Develop IPS as a companion diagnostic (CDx) for existing or novel therapies and leverage our network of 7,500+ oncologists to help drive clinical adoption.
Partnerships
Life Science research applications
IPS offers robust support for life sciences research, providing actionable insights in various applications.
Label expansion
Identify potential patient populations who might benefit from ICI treatments beyond their current labeling.Novel ICI combinations
Target populations with suboptimal responses to standard ICIs who may benefit from novel combination therapies.Trial design
Enhance patient selection and stratification in clinical trials, enabling more effective study designs.
Tailored access to IPS
We offer a full spectrum of capabilities—from data licensing to validation to adoption—ensuring support for your research needs.
Sequencing
Access IPS results through sequencing of retrospective tissue samples with concurrent Tempus xT and xR orders.
Multimodal data
Analyze IPS results across de-identified patient records that incorporate clinical, molecular, and imaging modalities through flexible licensing solutions.
Companion diagnostics
Partner with us to develop IPS as a CDx for an existing or novel therapy.
The information on this page is intended for life sciences companies and focuses on research and development applications.
This is AI-enabled precision medicine
This is the future of healthcare.